TOPLINE:

Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer. The interim analysis also showed meaningful improvement in overall survival, with median survival extending from 11.50 to 15.97 months.

METHODOLOGY:

While platinum-based chemotherapy is initially effective, about 70% of patients experience disease relapse that becomes platinum-resistant.

Relacorilant, a selective glucocorticoid receptor antagonist, has demonstrated synergy with paclitaxel in nonclinical tumor models. The combination with nab-paclitaxel was chosen for this study because it does not require corticosteroid coadministration.

Researchers conducted a randomized, controlled, open-

See Full Page